Evidence map›Paper›PMID 42122157›Full record

ArticleCancers2026

Extramedullary AML: Clinical and Molecular Features.

Yael Morgenstern, Claire Andrews, Eshetu G Atenafu, Steven Chan, Vikas Gupta, Mark D Minden, Dawn Maze, Aaron Schimmer, Andre Schuh, Karen Yee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yael MorgensternDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.ORCID 0000-0002-8525-5752
Claire AndrewsDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Eshetu G AtenafuDepartment of Biostatistics, University Health Network, Toronto, ON M5G 1X6, Canada.ORCID 0000-0002-4613-3680
Steven ChanDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Vikas GuptaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Mark D MindenDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Dawn MazeDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Aaron SchimmerDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Andre SchuhDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Karen YeeDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.ORCID 0000-0002-2572-9952
Hassan SibaiDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.ORCID 0000-0001-9030-8583

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myeloid leukemia with extramedullary disease (EMD-AML) represents a distinct clinical entity associated with diagnostic and therapeutic challenges, and its prognostic significance remains uncertain.

methodsA retrospective study of 617 adults with newly diagnosed AML (2005-2018) was conducted, analyzing 246 patients with EMD-AML and 371 without EMD involvement. The clinical characteristics and treatment outcomes were analyzed. Propensity score matching (PSM) was applied to adjust for baseline confounders.

resultsPatients with isolated EMD-AML and those with concurrent bone marrow involvement had comparable clinical outcomes. NPM1 mutations (48% vs. 25%,

conclusionsEMD-AML, whether isolated or concurrent with bone marrow disease, represents a high-risk entity characterized by poor long-term outcomes despite strong initial response rates. Obtaining tissue biopsies for molecular profiling may help improve risk stratification, identify targetable mutations and guide individualized treatment.

Indexed as

AMLextra meduallary AMLleukemiamyeloid sarcoma

Identifiers

PMID42122157
PMCPMC13162922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.